Literature DB >> 22396700

Recurrent very late stent thrombosis in a systemic lupus erythematous patient.

Dong-Yob Lee1, Jong-Pil Park, Sung-Jun Ko, Shin-Eun Lee, Sung-Hee Jhon, Ji-Hyun Lim, Jay-Young Rhew.   

Abstract

Coronary artery disease is the most important cause of mortality in patients with systemic lupus erythematous (SLE). After stenting for coronary artery disease in SLE patients similar to non-SLE patients, the risk of stent thrombosis is always present. Although there are reports of stent thrombosis in SLE patients, very late recurrent stent thrombosis is rare. We experienced a case of very late recurrent stent thrombosis (4 times) in a patient with SLE.

Entities:  

Keywords:  Drug-eluting stents; Lupus erythematosus, systemic

Year:  2012        PMID： 22396700      PMCID： PMC3291722          DOI： 10.4070/kcj.2012.42.2.118

Source DB:  PubMed          Journal:  Korean Circ J        ISSN： 1738-5520            Impact factor:   3.243


  12 in total

1.  Late in-stent thrombosis in a patient with systemic lupus erythematosus and hyperhomocysteinemia while on clopidogrel and aspirin.

Authors:  Andre C Olivier; Jay L Hollman
Journal:  J Invasive Cardiol       Date:  2006-06       Impact factor: 2.022

2.  Dilemma of drug-eluting stent implantation in a patient with systemic lupus erythematosus.

Authors:  Chi-Hang Lee; Mark Y Chan
Journal:  Int J Cardiol       Date:  2006-11-03       Impact factor: 4.164

3.  Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation.

Authors:  Cheol Whan Lee; Su-Jin Kang; Duk-Woo Park; Seung-Hwan Lee; Young-Hak Kim; Jae-Joong Kim; Seong-Wook Park; Gary S Mintz; Seung-Jung Park
Journal:  J Am Coll Cardiol       Date:  2010-05-04       Impact factor: 24.094

4.  Recurrent stent thrombosis associated with lupus anticoagulant due to renal cell carcinoma.

Authors:  D F Muir; A Stevens; R O Napier-Hemy; F Fath-Ordoubadi; N Curzen
Journal:  Int J Cardiovasc Intervent       Date:  2003

5.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  Mary J Roman; Beth-Ann Shanker; Adrienne Davis; Michael D Lockshin; Lisa Sammaritano; Ronit Simantov; Mary K Crow; Joseph E Schwartz; Stephen A Paget; Richard B Devereux; Jane E Salmon
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

6.  Myocardial infarction secondary to premature coronary artery disease as the initial major manifestation of systemic lupus erythematosus.

Authors:  S E Kassaian; H Goodarzynejad; S Darabian; Z Basiri
Journal:  Cardiovasc J Afr       Date:  2008 May-Jun       Impact factor: 1.167

7.  Acute coronary syndrome as a first presentation of systemic lupus erythematosus in a teenager: revascularization by hybrid coronary artery bypass graft surgery and percutaneous coronary intervention: case report.

Authors:  P K Mehta; H Samady; T A Vassiliades; W M Book
Journal:  Pediatr Cardiol       Date:  2007-12-01       Impact factor: 1.655

8.  Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years.

Authors:  Y S Haider; W C Roberts
Journal:  Am J Med       Date:  1981-04       Impact factor: 4.965

9.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

10.  Acute thrombosis after elective direct intracoronary stenting in primary antiphospholipid syndrome: a case report.

Authors:  Ho-Ming Su; Kun-Tai Lee; Chin-Sheng Chu; Sheng-Hsiung Sheu; Wen-Ter Lai
Journal:  Kaohsiung J Med Sci       Date:  2003-04       Impact factor: 2.744
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.